Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from SSY Group ( (HK:2005) ) is now available.
SSY Group Limited reported a significant decline in its unaudited operating results for the nine months ended September 30, 2025, with turnover decreasing by 31.6% and gross profit dropping by 46.1% compared to the previous year. The company attributes these declines to reduced sales volumes in its key product areas and increased price competition due to expanded volume-based procurement initiatives. The depreciation of the Renminbi against the Hong Kong dollar also impacted financial results, leading to a 56.6% decrease in profit attributable to shareholders.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$3.50 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group Limited operates in the pharmaceutical industry, focusing primarily on the production and sale of intravenous infusion solutions and ampoule injections. The company conducts the majority of its sales in the People’s Republic of China and is affected by the competitive pressures of both domestic and international markets.
Average Trading Volume: 14,592,622
Technical Sentiment Signal: Hold
Current Market Cap: HK$9.09B
Learn more about 2005 stock on TipRanks’ Stock Analysis page.